Cargando…
Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review
BACKGROUND: The neoadjuvant use of immune checkpoint inhibitors (ICIs) in resectable non-small-cell lung cancer (NSCLC) is currently an area of active ongoing research. The place of neoadjuvant ICIs in the treatment guidelines needs to be determined. We carried out a systematic review of published d...
Autores principales: | Ulas, E.B., Dickhoff, C., Schneiders, F.L., Senan, S., Bahce, I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414043/ https://www.ncbi.nlm.nih.gov/pubmed/34479033 http://dx.doi.org/10.1016/j.esmoop.2021.100244 |
Ejemplares similares
-
Neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: the more cycles, the better?
por: Ulas, Ezgi B., et al.
Publicado: (2023) -
Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer
por: Riano, Ivy, et al.
Publicado: (2023) -
Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial
por: Dickhoff, Chris, et al.
Publicado: (2020) -
Neoadjuvant immunotherapy in resectable non-small cell lung cancer at a checkpoint
por: Faltermeier, Claire M., et al.
Publicado: (2021) -
Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer
por: Pradhan, Monika, et al.
Publicado: (2021)